This work was supported by an unrestricted grant of the Deutsches Rotes Kreuz Blutspendedienst West, Hagen, Germany and by the Federal Ministry of Education and Research, Germany (BMBF FKZ 03Z2CN12).
BLOOD GROUP GENOMICS
Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues
Version of Record online: 11 MAR 2013
© 2013 American Association of Blood Banks
Volume 53, Issue 12, pages 3217–3223, December 2013
How to Cite
Flesch, B. K., Wesche, J., Berthold, T., Goldmann, T., Hundt, M., Greinacher, A. and Bux, J. (2013), Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues. Transfusion, 53: 3217–3223. doi: 10.1111/trf.12160
- Issue online: 9 DEC 2013
- Version of Record online: 11 MAR 2013
- Manuscript Accepted: 23 JAN 2013
- Manuscript Revised: 4 DEC 2012
- Manuscript Received: 8 OCT 2012
- Deutsches Rotes Kreuz Blutspendedienst West, Hagen, Germany
- Federal Ministry of Education and Research, Germany. Grant Number: BMBF FKZ 03Z2CN12
The HNA-3a antigen is an important antibody target in the pathophysiology of transfusion-related acute lung injury (TRALI). It is encoded by the choline transporter-like protein 2 (CTL2) gene, which exists in the two transcript variants TV1 and TV2, differing in the upstream promoter and coding region. Only TV1 has been demonstrated to enable choline transport across the cell membrane.
Study Design and Methods
The aim of this study was to determine the CTL2 transcript pattern in human peripheral blood cells and tissues and its capacity to bind HNA-3a antibodies. RNA was isolated from human whole blood, isolated neutrophils, mononuclear blood cells, leukoreduced platelets, human lung, liver, and colon. After reverse transcription, the single-stranded cDNA was amplified using primer combinations specific for the respective transcript. Plasmids containing the entire CTL2 coding cDNA of the transcript variant TV1 or TV2 served as controls. HEK293T cells expressing both variants were used to determine the binding of HNA-3a antibodies.
The shorter TV2 transcript was demonstrated in each RNA sample derived from human peripheral blood tested so far, as well as in human lung and liver, whereas the longer TV1 transcript was only detected in human lung and colon. TV1 and TV2 had the same binding capacity to HNA-3a antibodies.
The expression of TV1 and TV2 is tissue and cell specific, with peripheral blood cells expressing only TV2. This does not affect binding of HNA-3a antibodies. Whether the unequal expression might be relevant in the pathogenesis of TRALI remains to be investigated.